2016
Group Leader
Carles Besses Raebel
The group is studying molecular markers in chronic myeloproliferative neoplasms, mainly driver mutations but also mutations in epigenetic modifiers and genes involved in the splicing mechanism, and their role in monitoring the response to cytoreductive therapy and in the prognosis of patients. In addition, the group is searching for new mutations using exome sequencing techniques in those patients with essential thrombocythemia unmutated for JAK2, CALR and MPL genes. In addition, the role of circulating DNA as a tool to diagnose and monitor the response to therapy in myeloid neoplasms is an ongoing research project. Another area of research is the effect of new drugs in ex vivo cultures of neoplastic lymphoid cells obtained from lymphoma patients and determining the mechanisms underlying response/resistance, and identification of potential synergistic combinations. The clinical research in lymphoma is focused on the usefulness of natriuretic peptid and cardiovascular risk scales to predict anthracycline-induced cardiomyotoxicity in patients with diffuse large B-cell lymphoma.
Members
Eugènia Abella Monreal (Researcher)
Alberto Álvarez Larrán (Researcher)
Anna Angona Figueras (Technician)
Beatriz Bellosillo Paricio (Researcher)
Randa Ben Azaiz Ben Lahsen (Technician)
Laura Camacho Díaz (Technician)
Lierni Fernández Ibarrondo (Technician)
María Concepción Fernández Rodríguez (Technician)
Mariana Paola Ferraro Rosset (Technician)
Francesc Garcia Pallarols (Technician)
Eva Gimeno Vázquez (Researcher)
Carmen Jiménez Martínez (Researcher)
Anna Maria Massó Carreras (Research Assistant)
Silvia Pairet García (Technician)
Antonio Salar Silvestre (Researcher)
Blanca Sánchez González (Researcher)
María Alicia Senín Magán (Technician)
María Elena Torres Grande (Technician)
more info
Main Publications
• Álvarez-Larran A, Pereira A, Guglielmelli P, Hernández-Boluda JC, Arellano-Rodrigo E, Ferrer-Marín F, Samah A, Griesshammer M, Kerguelen A, Andreasson B, Burgaleta C, Schwarz J, García-Gutiérrez V, Ayala R, Barba P, Gómez-Casares MT, Paoli C, Drexler B, Zweegman S, McMullin MF, Samuelsson J, Harrison C, Cervantes F, Vannucchi AM, Besses C. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with CALR mutation. Haematologica 2016; 101(8): 926-931. IF 6.671. Q1.
• Godfrey AL, Chen E, Massie CE, Silber Y, Pagano F, Bellosillo B, Guglielmelli P, Harrison CN, Reilly JT, Stegelmann F, Bijou F, Lippert E, Boiron JM, Döhner K, Vannucchi AM, Besses C, Green AR. STAT1 activation in association with JAK2 exon 12 mutations. Haematologica 2016; 101(1): e15-e19. IF 6.671. Q1.
• Robles EF, Mena-Varas M, Barrio L, Merino-Cortes SV, Balogh P, Du MQ, Akasaka T, Parker A, Roa S, Panizo C, Martín-Guerrero I, Siebert R, Segura V, Agirre X, Macri-Pellizeri L, Aldaz B, Vilas-Zornoza A, Zhang S, Moody S, Calasanz MJ, Tousseyn T, Broccardo C, Brousset P, Campos-Sánchez E, Cobaleda C, Sánchez-García I, Fernández-Luna JL, García-Muñoz R, Peña E, Bellosillo B, Salar A, Baptista MJ, Hernández-Rivas JM, González M, Terol MJ, Climent J, Ferrández A, Sagaert X, Melnick AM, Prosper F, Oscier DG, Carrasco YR, Dyer MJ, Martínez-Climent JA. Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics. Nat Commun 2016; 7: 11889. IF 11.329. Q1.
• Van Emburgh BO, Arena S, Siravegna G, Lazzari L, Crisafulli G, Corti G, Mussolin B, Baldi F, Buscarino M, Bartolini A, Valtorta E, Vidal J, Bellosillo B, Germano G, Pietrantonio F, Ponzetti A, Albanell J, Siena S, Sartore-Bianchi A, Di Nicolantonio F, Montagut C, Bardelli A. Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nat Commun 2016; 7: 13665. IF 11.329. Q1.
• Verstovsek S, Vannucchi AM, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Kirito K, Besses C, Hino M, Moiraghi B, Miller CB, Cazzola M, Rosti V, Blau I, Mesa R, Jones MM, Zhen H, Li J, Francillard N, Habr D, Kiladjian JJ. Ruxolitinib versus best available therapy in patients with Polycythemia Vera: 80 Week follow up from the RESPONSE trial. Haematologica 2016; 101(7): 821-829. IF 6.671. Q1.
Ongoing Research Projects
• Molecular characterization of Non-Small Cell Lung Cancer (NSCLC) KRAS mutant tumors: clinical implications of new biomarkers
− Fundació La Marató de TV3 (20130530)
− From 2014 to 2017
− Principal investigator: Bellosillo Paricio, Beatriz
• Estudio de la evolución clonal molecular mediante análisis de secuenciación masiva en neoplasias mieloproliferativas JAK2V617F positivas y su correlación con la carga de JAK2V617F
− Fondo de Investigación Sanitaria. ISCIII (PI13/00557)
− From 2014 to 2016
− Principal investigator: Álvarez Larrán, Alberto
• Caracterización de la trombocitemia esencial jak2v617f y mpl negativa mediante secuenciación del exoma
− Fondo de Investigación Sanitaria. ISCIII (PI13/00393)
− From 2014 to 2017
− Principal investigator: Bellosillo Paricio, Beatriz
• Caracterización mediante secuenciación masiva de las mutaciones asociadas con fallo precoz al tratamiento de primera línea en linfoma folicular
− Fondo de Investigación Sanitaria. ISCIII (PI15/00459)
− From 2016 to 2018
− Principal investigator: Salar Silvestre, Antonio
• Molecular characterization of myeloid malignancies in tumoral circulating free DNA and exosomes
− Gilead España GLD16/00064
− From 2016 to 2018
− Principal investigator: Besses Raebel, Carles
Participation in Research Networks
• GEMFIN (Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas)
• MPNEuronet (http://www.mpneuronet.eu/)
• GELCAB (Grup d’Estudi de Limfomes de Catalunya i Balears)
• GELTAMO (Grupo Español de Linfomas y Trasplante Autólogo de Medula Ósea)
• ELN (European Leukemia Net)
Group’s Recognitions
• Officially recognised as a consolidated research group by the Generalitat de Catalunya: Grup de Recerca Clínica Aplicada en Hematologia (2014 to 2017)
− Agència de Gestió d'Ajuts Universitaris i de Recerca (SGR 567)
− Principal investigator: Besses Raebel, Carles
Clinical Trials Signed in 2016
• Estudio fase III nacional, multicéntrico, abierto, aleatorizado, de tratamiento de mantenimiento con lenalidomida y dexametasona versus lenalidomida, dexametasona y MLN9708 tras trasplante autólogo de progenitores hematopoyéticos para pacientes con mieloma múltiple sintomático de nuevo diagnóstico
− Register: GEM201MAIN
− Principal investigator: Abella Monreal, Eugènia
• A Phase 3, Randomized, Double-blind Study of Duvelisib Administered in Combination with Rituximab and Bendamustine vs Placebo Administered in Combination with Rituximab and Bendamustine in Subjects with Previously-Treated Indolent Non-Hodgkin Lymphoma
− Register: IPI-145-22
− Principal investigator: Salar Silvestre, Antonio
• Estudio observacional retrospectivo para describir el manejo de pacientes con linfoma de células del manto en recaída o refractario en la práctica clínica habitual (IMORS)
− Register: JAN-IBR-2015-01
− Principal investigator: Salar Silvestre, Antonio
• Evaluación de la efectividad y seguridad de Pixantrona en el tratamiento del Linfoma no Hodgkin de linfocitos B agresivo, multirrecidivante o resistente al tratamiento. Registro internacional.
− Register: SER-PIX-2016-01(PIXA-Registry)
− Principal investigator: Salar Silvestre, Antonio
• Registro Español de Trombocitemia Esencial
− Register: GEE-AAS-2015-01
− Principal investigator: Álvarez Larrán, Alberto
• A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy
− Register: 2215-CL-0201
− Principal investigator: Pedro Olivé, Carme
C/ Doctor Aiguader, 88
08003 Barcelona
(+34) 93 316 04 00
info@imim.es